Sorry, but your browser does not support the video tag. (BPT) – When her infant son Sam turned one, Robin Blackwood sensed something wasn’t right. “He wasn’t ...

The MarketWatch News Department was not involved in the creation of this content. -- Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi ...

LAWRENCE, KANSAS — The most common inherited cause of intellectual disability, fragile X syndrome, is caused by mutations in a single gene, the FMR1 gene. FMR1 mutations occur when parents possess a ...

In a comprehensive Genomic Press Interview, researchers from the University of Texas Health Science Center at San Antonio and Hirosaki University have uncovered critical new insights into the ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...

The cover artistically integrates multiple elements central to investigating the developmental origins of Fragile X syndrome. A vibrant DNA double helix structure rendered in rainbow iridescent colors ...

GPs have been urged to test patients for a genetic condition that is the most common inherited cause of learning disability. There is a “surprising lack of awareness” around Fragile X, experts said.

A new study suggests a potential molecular strategy for treating fragile X syndrome, an inherited neurodevelopmental disorder that causes autism spectrum disorder and intellectual disability. This ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...

Still, like many parents and caregivers of individuals with Fragile X — the most common inherited form of autism and it is one of the most common inherited causes of developmental and intellectual ...

Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan ...